Hypercharge to Announce Fourth Quarter and Fiscal Year 2025 Financial Results on July 29, 2025
Hypercharge's Audited Consolidated Financial Statements, Management's Discussion and Analysis, and Annual Information Form will be available on the Company's website at https://hypercharge.com/investors/, and under the Company's SEDAR+ profile at https://www.sedarplus.ca/.
-##-
About HyperchargeHypercharge Networks Corp. (TSXV: HC) (OTCQB: HCNWF) (FSE: PB7) is a leading provider of smart electric vehicle (EV) charging solutions for residential and commercial buildings, fleet operations, and other rapidly growing sectors. Driven by its mission to accelerate EV adoption and enable the shift towards a carbon neutral economy, Hypercharge is committed to offering seamless, simple solutions including industry-leading hardware, innovative and integrated software, and comprehensive services, backed by a robust network of public and private charging stations. Learn more: https://hypercharge.com/
On behalf of the Company,Hypercharge Networks Corp.David Bibby, President & CEO
Contact
Media & Investor Relations:Kyle Kingsnorth, Head of Marketingkyle.kingsnorth@hypercharge.com | +1 (888) 320-2633
Forward-Looking Statements
This news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "could", "should", "anticipate", "will", "estimates", "believes", "intends", "expects" and similar expressions which are intended to identify forward-looking statements. Forward-looking statements are inherently uncertain, and the actual performance may be affected by a number of material factors, assumptions and expectations, many of which are beyond the control of the Company. Readers are cautioned that assumptions used in the preparation of any forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company. Readers are further cautioned not to place undue reliance on any forward-looking statements, as such information, although considered reasonable by management of the Company at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
The forward-looking statements contained in this news release are made as of the date of this news release, and are expressly qualified by the foregoing cautionary statement. Except as expressly required by securities law, the Company undertakes no obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/258802
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
VitalHub Announces Q2 2025 Conference Call Date
TORONTO, July 21, 2025 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX:VHI) (OTCQX:VHIBF) (the 'Company' or 'VitalHub') announced today that it will release financial results for its second quarter 2025 ended June 30, 2025 after market close on August 7, 2025. The Company will hold a conference call on August 8, 2025 at 9:00am EST, hosted by CEO Dan Matlow and CFO Brian Goffenberg with a Q&A session to follow. To register for the conference call please visit: About VitalHub VitalHub is a leading software company dedicated to empowering health and human services providers globally. VitalHub's comprehensive product suite includes electronic health records, operational intelligence, and workforce automation solutions that serve over 1,000 clients across the UK, Canada, and other geographies. The Company has a robust two-pronged growth strategy, targeting organic opportunities within its product suite and pursuing an aggressive M&A plan. VitalHub is headquartered in Toronto with over 500 employees globally, across key regions and the VitalHub Innovations Lab in Sri Lanka. For more information about VitalHub (TSX:VHI) (OTCQX:VHIBF), please visit and LinkedIn. Contact Information Christian Sgro, CPA, CA, CFAHead of IR and M&A Specialist(365) Dan MatlowChief Executive Officer, Director(416)
Yahoo
25 minutes ago
- Yahoo
Movora Becomes Exclusive Distributor of Aesculap Surgical Power Systems in North America
St. Augustine, Florida--(Newsfile Corp. - July 21, 2025) - As of Tuesday, May 20, 2025, Movora is proud to announce it has entered into an exclusivity agreement with Aesculap, a division of B. Braun VetCare, to become the sole distributor of Aesculap Surgical Power Systems and power accessories in the United States and Canada. This partnership further strengthens Movora's commitment to providing premium orthopedic and surgical solutions to veterinary professionals across North America. By securing exclusive distribution rights, Movora will ensure enhanced access to Aesculap's innovative power systems, reinforcing its role as a leader in the veterinary surgical space. "Movora has a long-standing relationship with Aesculap Surgical Power products as part of our core orthopedic business, and we are very excited about the exclusive partnership in North America, our largest market," said Guy Spörri, CEO of Movora. "This agreement represents a significant step forward in our mission to support veterinary professionals with world-class surgical technologies." Achim Ott, Export Sales Manager at Aesculap/B. Braun VetCare, added: "We are very much looking forward to our continued cooperation and hope for further successful business together." The agreement officially designates Movora as the exclusive North American distributor of Aesculap Surgical Power and accessories, ensuring streamlined service, consistent availability, and expert support for customers across the U.S. and Canada. Non-Movora Aesculap Power Customers will utilize Movora for all Aesculap Power Equipment Repairs moving forward. Please visit for more information and to get started. For more information, visit Media Contacts:Korrie Wilhelm, VP Global MarCom, Brand Strategy & Achim Ott, Export Sales ManagerBBraun VetCare/ To view the source version of this press release, please visit Sign in to access your portfolio
Forbes
28 minutes ago
- Forbes
Sarepta Therapeutics: Why Is SRPT Stock Crashing?
CANADA - 2025/06/08: In this photo illustration, the Sarepta Therapeutics logo is seen displayed on ... More a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images) Sarepta Therapeutics has plunged to new lows below $13, down over 35% in recent trading, after rejecting the FDA's request to voluntarily halt all shipments of Elevidys following a third death tied to the gene therapy. Just days after our previous analyses highlighted the company's apparent undervaluation following its restructuring, its defiant stance has now triggered fresh investor concerns, validating the regulatory risks associated with biotech stocks. The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns. With Elevidys generating 43% of Sarepta's total revenues and holding traditional approval since June 2024 for ambulatory patients, any regulatory challenge poses existential threats to the company. FDA Commissioner Marty Makary's statement that he's "taking a hard look" at whether Elevidys should remain on the market suggests potential forced withdrawal if voluntary compliance fails. The recent $400 million restructuring cost savings appear insufficient against potential revenue loss from broader market restrictions. Sarepta's confrontational approach toward federal regulators is creating unprecedented uncertainty, even for biotech investors who typically have a high tolerance for risk. This unwillingness to proactively address safety concerns demonstrates poor risk management, especially at a time when regulatory goodwill is crucial. Situations like this underscore our consistent message about the inherent risks of investing in single stocks and highlight why professionally managed portfolios are often a better choice. In fact, regulatory risk is just a small part of the risk assessment framework we apply while constructing the Trefis High Quality (HQ) Portfolio which, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride as evident in HQ Portfolio performance metrics.
